While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...
When Silence Therapeutics unveiled its latest zerlasiran phase 2 data at the American Heart Association (AHA) conference in ...
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...
Merck reported adjusted earnings of $1.72 per ... charge of 23 cents related to M&A deals with LaNova Medicines and Hansoh Pharma. Revenues rose 7% year over year (9% excluding Fx) to $15.62 ...
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.
CNN on MSN13d
A little-known Chinese company made a drug that beat the world’s biggest-selling medicineChina’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend isn’t confined to Big Tech: It has been quietly happening in the ...
Merck is one of the largest pharmaceutical ... HS-10535, with China-based Hansoh Pharma. It signed a similar licensing deal with LaNova Medicines for the development of LM-299, a potential cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results